The Food and Drug Administration intends to update its Risk Evaluation and Mitigation Strategy requirements for extended-release and long-acting opioid analgesics, and extend the same requirements to immediate-release opioid analgesic products, FDA Commissioner Scott Gottlieb, M.D., announced this week. The existing REMS requires companies that manufacture extended-release and long-acting opioid analgesics to make education programs available to prescribers and patients. According to Gottlieb, the new REMS will modify the prescriber education blueprint to include more information on pain management, safe use of opioid analgesics, addiction medicine and opioid use disorders. The REMS also will require manufacturers to make training available to more than physician prescribers, such as nurses and pharmacists involved in pain management. In addition, he said the agency is exploring whether provider education should be mandatory. According to FDA, about 90% of opioid prescriptions in the U.S. are for immediate-release formulations.

Headline
The Department of Health and Human Services Nov. 12 made two announcements  regarding the development of mental health treatments for veterans and other…
Headline
A study on substance-related emergency department visits and hospitalizations published Nov. 4 by The American Journal of Psychiatry found that cannabis was…
Headline
Erica Taylor, M.D., orthopedic surgeon and vice president of health equity at Duke Health, shares how the organization’s frontline liaison network is helping…
Headline
The AHA has released its latest downloadable Fast Facts infographic providing statistics on the number of behavioral health hospitals and hospital services in…
Blog
To reduce suicide in the healthcare workforce, hospitals and health systems must create an environment where workers feel safe asking for help.By Susan…
Headline
The Department of Health and Human Services announced Sept. 8 through the Substance Abuse and Mental Health Services Administration that it will award $383.4…